<0.001 EU per 1 μg of the peptide by the LAL method
For reduction of mortality in patients with severe sepsis.
Examples of Clinical Use:
The product is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. The product inhibits factor Va and VIIIa, thereby reducing the coagulability of blood.
Mechanism of action:
Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.
Drotrecogin alfa (also known as activated human protein C) is a recombinant protein C (protein C) variant distinct from the naturally occurring protein C in the body. It is further activated to produce stronger anticoagulant and anti-inflammatory effects. Drotrecogin alfa is primarily used to treat severe septic shock, which is a severe infection resulting in hypotension and multiple organ dysfunction. It improves patient survival by inhibiting the coagulation process and inhibiting the inflammatory response. Drotrecogin alfa acts on the coagulation system and is able to inhibit the activity of factors V and VIII, thereby reducing the risk of thrombosis. In addition, it can also reduce the inflammatory response by inhibiting the activation of inflammatory cells and the release of mediators. It should be noted that the method and dose of Drotrecogin alfa need to be determined according to the clinician's recommendation and the specific condition of the patient. In addition, the manufacture and sale of Drotrecogin alfa has been discontinued and it is no longer recommended for routine use.
Clinical use of protein C
The primary clinical use of Drotrecogin alfa (activated human protein C) is in the treatment of severe septic shock. Septic shock is a severe condition of hypotension and multiple organ dysfunction caused by infection. Drotrecogin alfa can improve the survival of patients with septic shock by inhibiting the coagulation process and inhibiting the inflammatory response. Its mechanism of action includes inhibition of factor V and factor VIII activity, reducing the risk of thrombosis. In addition, it inhibits the activation of inflammatory cells and the release of inflammatory mediators, thereby reducing the inflammatory response. However, it should be noted that the effect of Drotrecogin alfa use is controversial. Initial clinical trials showed improved survival in patients with septic shock, but subsequent studies have shown inconsistent results. Therefore, the manufacture and distribution of Drotrecogin alfa has been discontinued and it is no longer recommended for routine use. Most important for the treatment of septic shock is to control the infection and maintain the function of tissues and organs through early and appropriate antibiotic therapy, fluid resuscitation and supportive therapy. When making a treatment plan, it is also necessary to judge and decide according to the specific condition of the patient and the professional opinion of the clinician.
Related Pathways of protein C
The action pathway of Drotrecogin alfa (activated human protein C) is mainly involved in the following aspects: (1) Anticoagulant effect: Drotrecogin alfa inhibits the coagulation process by activating endogenous protein C. Activated protein C is able to degrade factor Va and factor VIIIa, reduce the risk of thrombosis, and maintain normal blood circulation in the blood vessels. (2) Anti-inflammatory effect: In addition to its anticoagulant effect, Drotrecogin alfa also inhibits inflammation and regulates the immune system. It inhibits the production and release of inflammatory mediators, inhibits the activation of inflammatory cells (such as macrophages), and reduces the damage of inflammatory response to tissues and organs. (3) Promote fibrinolysis: Drotrecogin alfa can also promote fibrinolysis, that is, by activating plasmin to accelerate the degradation of fibrin, thereby preventing the formation of blood clots. Through these pathways, Drotrecogin alfa can achieve anticoagulant, anti-inflammatory and profibrinolytic effects, thus playing a role in the treatment of severe septic shock. "However, it should be emphasized that Drotrecogin alfa is currently discontinued and no longer recommended for routine use, and its clinical applicability is determined based on the physician's guidance and the individual patient's condition."
Protein C Related Pipeline under development
The manufacture and distribution of Drotrecogin alfa (activated human protein C) has been discontinued and is no longer recommended for routine treatment. Drotrecogin alfa had previously been approved by the Food and Drug Administration (FDA) for the treatment of severe septic shock. However, due to the results of subsequent studies questioning its efficacy and lack of sufficient evidence to support its long-term clinical value, pharmaceutical companies have decided to stop production and withdraw the relevant products. In current clinical practice, the focus of treating septic shock has shifted to early and appropriate antibiotic therapy, fluid resuscitation, and supportive care. Of course, research continues for new treatments and drugs, but there is no new Drotrecogin alfa pipeline in the pipeline.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.